Becton Dickinson CPO Detect Test

Hologic has introduced an Open Access functionality that will allow CLIA-certified laboratories to develop laboratory developed tests to run on its fully automated Panther Fusion platform. Labs will be able to run their LDTs simultaneously with commercially available IVD assays, and results will release automatically to laboratory information systems.

The Open Access functionality is enabled by the new myAccess software, which is designed to help laboratories create protocols, analyze data, set thresholds, and interpret results, Hologic said.

Vela Diagnostics has commercialy launched the Great Basin infectious disease diagnostic system in Europe and the US. In preparation for the launch, Vela has relisted the products with the US and Food and Drug Administration and CE-IVD under its name. Initial site placements are evaluating the firm's Stool Bacterial Pathogens Panel. The evaluation will then be followed by Great Basin's five additional assays, including the Staph ID/R Blood Culture panel, Group B Strep Test, Shiga Toxin Direct Test, Bordetella Direct Test, and the Toxigenic C. diff test. All the assays use the Great Basin Analyzer, which is designed to perform automated sample extraction and chip-based detection in a fully enclosed cartridge with integrated data analysis.

Veritas Genetics announced it is now offering myGenome Premium and myGenome Diagnostic services, in addition to its $999 myGenome Standard service. The premium service is priced at $1,499 (or $500 for customers of the standard service) and is for those want a more indepth analysis of their carriers status, cancer risks, and cardiovascular risks. Within the premium service, customers will receive information on more than 400 genes associated with around 20 actionable conditions and on 125 genes linked to more than 200 carrier conditions. 

The $2,999 myGenome Diagnostic service ($1,999 for customers of the standard service) is for those with a personal or family history of a genetic condition, and providers interpretation of all genes known to be associated with the disease. This service is availalbe for adults and pediatric patients, and customers will also receive reports included in the standard service.

Within myGenome Standard, Veritas is also adding a new section that inlcudes "lower-impact genetic findings" associated with 15 commone diseases, for which individuals may be able to lower their risks via lifestyle changes.

Agilent Technologies has launched Agilent OnePGT, a genome-wide, next-generation sequencing solution for preimplantation genetic testing. OnePGT allows parallel detection of multiple monogenic disorders, translocations, and aneuploidies from a single biopsy, going from biopsy to a single comprehensive report in a matter of days, Agilent said. The test is run on the company's Alissa platform, allowing for automatic calling of genetic abnormalities with built-in quality control metrics and an audit trail. This solution provides fertility specialists more comprehensive PGT data in order to help them identify the most viable embryos for transfer.

Vela Diagnostics has launched a new version of its Sentosa SQ HCV Genotyping Assay with improved reporting and data-interpretation features. The test uses next-generation sequencing to detect HCV genotypes 1, 2, 3, 4, 5, and 6, and subtypes 1a and 1b, and to report HCV variants in clinically relevant regions of NS3, NS5A and NS5B genes to allow drug-resistance assessment. This assay offers an integrated solution from sample to result in approximately two days with hands-on time of less than 2.5 hours.

Sirona Dx has announced the launch of its Oncocyst PD-L1 assay. The tool uses IncellDx technology to detect and quantify abnormal bladder cells and immune cells from urine cytology specimens that express the immune-oncology marker PD-L1 using multi-parameter flow cytometry and bioinformatics. Sirona's algorithm uses aneuploidy/DNA content in cells from the bladder. Researchers can perform the high-throughput, non-subjective assay in less than three hours, the firm said.

Cytek Biosciences has launched its Northern Lights flow cytometry system. The platform, the company said, makes three lasers and more than 24 colors possible at an affordable price. Cytek also launched two accessories to its flow cytometry solutions: the 561 nm laser, and a new plate reader. THe laser, which is availalbe for Cytek Aurora models only, adds 10 more fluorescence detection channels, it said, while the new plate reader offers walk-away capabilities and support 96-well plates, three throughput modes, and user customizable modes.